Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcturus Therapeutics Holdings (ARCT) Non-Current Debt (2018 - 2025)

Arcturus Therapeutics Holdings' Non-Current Debt history spans 7 years, with the latest figure at $15.0 million for Q1 2025.

  • For Q1 2025, Non-Current Debt changed N/A year-over-year to $15.0 million; the TTM value through Mar 2025 reached $15.0 million, changed N/A, while the annual FY2021 figure was $40.6 million, 193.49% up from the prior year.
  • Non-Current Debt reached $15.0 million in Q1 2025 per ARCT's latest filing, down from $20.0 million in the prior quarter.
  • In the past five years, Non-Current Debt ranged from a high of $58.1 million in Q1 2021 to a low of $15.0 million in Q1 2025.
  • Average Non-Current Debt over 4 years is $37.7 million, with a median of $39.2 million recorded in 2022.
  • Peak YoY movement for Non-Current Debt: skyrocketed 286.92% in 2021, then crashed 37.57% in 2023.
  • A 4-year view of Non-Current Debt shows it stood at $40.6 million in 2021, then decreased by 21.15% to $32.0 million in 2022, then plummeted by 37.57% to $20.0 million in 2023, then fell by 25.0% to $15.0 million in 2025.
  • Per Business Quant, the three most recent readings for ARCT's Non-Current Debt are $15.0 million (Q1 2025), $20.0 million (Q3 2023), and $32.0 million (Q3 2022).